| Feature Type | Standardized | Nominal ANOVA | ||||
|---|---|---|---|---|---|---|
| mRNA | LFM-A13 | GDSC1000 | pan-cancer | AAC | -0.063 | 0.06 |
| mRNA | RAF265 | CCLE | pan-cancer | AAC | -0.09 | 0.07 |
| mRNA | AS601245 | GDSC1000 | pan-cancer | AAC | -0.063 | 0.07 |
| mRNA | cabozantinib | CTRPv2 | pan-cancer | AAC | -0.067 | 0.07 |
| mRNA | ibrutinib | CTRPv2 | pan-cancer | AAC | 0.075 | 0.07 |
| mRNA | Vorinostat | CTRPv2 | pan-cancer | AAC | 0.059 | 0.07 |
| mRNA | Elesclomol | GDSC1000 | pan-cancer | AAC | -0.06 | 0.07 |
| mRNA | AZD6482 | GDSC1000 | pan-cancer | AAC | -0.057 | 0.07 |
| mRNA | regorafenib | CTRPv2 | pan-cancer | AAC | -0.067 | 0.07 |
| mRNA | oligomycin a | CTRPv2 | pan-cancer | AAC | -0.063 | 0.07 |